We explored the efficacy of the IGEV regimen (ifosfamide, gemcitabine, vinorelbine and prednisone) combined with a fixed dose of lenograstim (263 lg/day) to mobilize peripheral blood stem cells (PBSCs) in 90 Hodgkin's lymphoma patients. The median total CD34 þ cells/ll peak, colony-forming units granulocyte-macrophage and white blood cells for all individual collection sets were 85/ll, 12 Â 10 4 /kg and 20 700/ll, respectively. An adequate number of CD34 þ cells (more than 3 Â 10 6 or 6 Â 10 6 CD34 þ cells/kg depending on whether single or tandem high-dose chemotherapy was used) were collected in 89 out of 90 (98.7%) mobilized patients, whereas the only failure reached 2.3 Â 10 6 CD34 þ cells/kg. The median CD34 þ cell collections were 11 Â 10 6 /kg (range 2.3-39 Â 10 6 /kg) and 10 Â 10 6 /kg (range 6-22.0 Â 10 6 /kg) with a median of 1 and 2 leukaphereses for patients eligible for single high-dose treatment and for candidates for tandem transplant, respectively. Target yields were reached in 71.43 and 49.09% and additionally in 17.14 and 43.64% of cases after the first and second apheresis procedures, respectively. Hematological and non-hematological side effects were acceptable, and no toxic deaths occurred. Thirty-four patients received a single and 47 received tandem transplantation with rapid engraftment. These results confirm that the IGEV regimen with lenograstim support can be used successfully and safely to mobilize PBSCs.
Introduction
Despite high-dose chemotherapy (HDCT) with autologous peripheral blood stem cell (PBSC) support being universally recognized as the gold standard for recurrent/ refractory Hodgkin's lymphoma (HL), the optimal induction regimen, has yet to be defined clearly. [1] [2] [3] [4] An ideal salvage regimen should combine a high response rate with acceptable hematological and non-hematological toxicities, and the ability to mobilize a sufficient number of hematopoietic progenitors for rapid and stable engraftment after HDCT.
Most previous reports on HDCT do not provide data on CD34 þ cell mobilization, and details on PBSC mobilization and collection are reported in a limited number of studies. [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] Recently we completed a phase II trial of gemcitabine combined with ifosfamide, vinorelbine and prednisolone (IGEV) in patients with refractory or recurrent HL, and reported a high response rate. 20 The study objectives were to evaluate the mobilizing potential of IGEV chemotherapy in 90 patients, to explore issues related to stem cell yield and optimal timing for harvesting, and also to identify risk factors affecting collections. We also compared the IGEV regimen with the most common salvage chemotherapy combinations reported in the literature.
Patients and methods

Patients
From November 1997 to July 2006, 105 patients with relapsed or primary refractory HL after chemotherapy with or without radiotherapy were placed on a study protocol consisting of four cycles of combined ifosfamide, gemcitabine, vinorelbine and prednisone (IGEV). The protocol was approved by the ethics committee and written informed consent was obtained from all participants. Fifteen patients were not mobilized for various reasons, specifically progression before the third IGEV cycle in six cases, assignment to allogeneic transplantation in eight cases and because HDCT had not been planned in one case. All 90 mobilized patients had received at least one previous chemotherapy combination ranging from four to eight courses as a function of the initial stage of the disease. Most patients (80%) had been treated with one regimen, the range being from one to four. All patients received an anthracycline-containing regimen.
Chemotherapy and stem cell collection As already described, 20 A fixed dose of lenograstim (263 mg/day) was given from day 7 to day 12 of each course or up to apheresis during the mobilizing phase. Four courses of chemotherapy were planned, provided that at least partial remission was evidenced after the second cycle. Tumor manifestations were reassessed after the second and fourth treatment cycles using the same baseline imaging technique throughout the study. PBSC collection was performed after the first or second course in the first 11 patients, to test the mobilizing potential of the regimen, and thereafter after the third treatment course whenever an objective response was observed. A target yield of at least 3 Â 10 6 CD34 þ cells per kg of body weight was planned to support each high-dose chemotherapy. A PBSC yield below 3.0 Â 10 6 /kg was considered a failure. According to our protocols during different periods, patients were assigned to receive a single HDCT procedure with thiotepa-melphalan ( 21 Leukapheresis and stem cell cryopreservation All patients underwent a routine complete blood count every other day starting from day 7 after each chemotherapy course. During the mobilization cycle, daily peripheral blood CD34 þ monitoring was started when the ANC reached 1 Â 10 9 /ml, and apheresis was performed when the peripheral blood CD34 þ cell count exceeded 10 cells/ml. CD34 cells were harvested using a COBE Spectra separator (COBE, Lakewood, CO, USA), software version 5.1 and 6.0, with a collection pump speed of 2400 g/min. Blood was collected via a central venous access device or from peripheral veins, and the patient's estimated blood volume was processed 2.7 times. Stem cells were cryopreserved using a Nicol Plus PC device (Air Liquide, DMC, Marne La Valle´e, France) and a mixture of autologous plasma and DMSO (LiStarFISH; final concentration 10%), and then stored in liquid nitrogen.
CD34 þ count CD34 þ count was performed on aliquots of apheresis samples using a single platform flow cytometric method based on International Society for Haematotherapy and Graft Engineering gating strategy: 100 ml of diluted cells was incubated in tubes containing antibodies against CD45-FITC/CD34-PE (Stem-kit Reagent, Immunotech, Beckman Coulter, Paris, France) and a viability dye 7-amino actinomycin D (7-AAD). Cells were lysed with NH 4 Cl. All tubes were incubated for 20 min at room temperature, protected from light. Prior to acquisition of the sample, 100 ml of Stem-Count Fluorospheres or FlowCount Fluorospheres was added to each tube. A Beckman Coulter Cytomics FC 500 flow cytometer with CXP software package was used for data acquisition and analysis. Alignment and calibration were performed daily by means of Coulter Flow-Check and Flow-Set fluorospheres. One hundred thousand CD45 þ events were collected in the cytofluorimeter. The absolute count was expressed as number of cells per microliter. The absolute CD34 þ cell number per apheresis pack was obtained by multiplying the absolute count per microliter by dilution factor, pack volume (in milliliters) and by 10 6 (to convert cell/ml to cell Â 10 6 /pack).
CFU-GM
Human clonogeneic progenitor assays were performed by plating stem cell populations at a concentration ranging between 1 Â 10 4 cells and 1 Â 10 5 cells into a methylcellulose formulation (MethoCult H4534, Stem Cell Technologies, Vancouver, British Columbia, Canada) containing 30% fetal bovine serum, 1% bovine serum albumin, 5% serumcontaining phytohemagglutinin-stimulated human leukocyte conditioned medium, 10 À4 M 2-mercaptoethanol, 2 mM L-glutamine, 2 U/ml erythropoietin, 100 U/ml penicillin, 0.4 mg/ml streptomycin and 1% methylcellulose in Iscove's MDM. Duplicate cultures were plated and incubated at 37 1C in a humidified atmosphere of 5% carbon dioxide. Differential colony counts were scored after 14 days by morphological characteristics using an inverted microscope.
Engraftment assessment
Engraftment was defined as the first day when ANC of 0.5 Â 10 9 /l was reached (lasting for at least 3 days) after the initial nadir post peripheral blood stem cell transplant.
Various definitions are used to describe platelet engraftment; we applied the International Bone Marrow Transplant Registry (IBMTR) criteria, according to which the day of platelet engraftment is defined as the first day of three consecutive complete blood counts with platelets of 20 Â 10 9 /l after the initial nadir post peripheral blood stem cell transplant in the absence of platelet transfusion.
Statistical analysis
Data were described as number and percentage or median and range where appropriate. Spearman's correlation test was used to compare CD34 cells/ml and CD34 leukapheresis products, and also CD34 m/l and colonyforming units granulocyte-macrophage (CFU-GM)/kg. The Mann-Whitney U-test was applied to compare the influence of variables on CD34/kg, CFU-GM/kg and on the day of platelet and neutrophil recovery after high-dose therapy. All calculations were performed with Stata 9 (www.stata.com).
Results
Stem cell collection
Leukapheresis was performed after the first, second, third and fourth cycles of chemotherapy in 4, 7, 71 and 8 patients, respectively. Patient characteristics are listed in Table 1 . The time from the first day of IGEV to the first day of leukapheresis was 13 days (range 10-17). Seventy-six percent (69/90) of patients began the harvesting procedure between days 13 and 15. On the first day of apheresis, the following laboratory values were observed: median number of white blood cells 20 700/ml (range 1700-58 450), hemoglobin 11.8 g/dl (range 9.7-15.3) and platelet count 87 000/ ml (range 29 000-289 000). The median total CD34 þ cells/ ml peak and CFU-GM for all individual collection sets were 85/ml (range 16.6-482) and 12 Â 10 4 /kg (range 9.6-385), respectively.
An adequate number of CD34 þ cells were collected in 89 out of 90 (98.7%) mobilized patients, whereas the only failed attempt reached 2.3 Â 10 6 CD34 þ cells/kg ( Table 2 ). The median CD34 þ cell collections were 11 Â 10 /kg) with a median of 1 (range 1-3) and 2 (range 1-3) leukaphereses for patients eligible for single high-dose treatment and for candidates to tandem transplant, respectively. Overall the target yields of 3 Â 10 6 and 6 Â 10 6 CD34 þ cells/kg were reached in 71.43 and 49.09% of cases, and additionally in 17.14 and 43.64%, after the first and second apheresis procedure, respectively. There were no significant differences in the total number of CD34 þ cells per leukapheresis and the total number of CD34 þ cells in patients weighing p or 470 kg (Table 3) 
Treatment delivery and toxicity
Treatment compliance during chemotherapy was good, and no patient refused to complete the treatment program. Only one treatment toxicity-related admission to the hospital occurred. No treatment-related deaths have been documented so far. Out of 313 cycles evaluated, 13 (4.2%) were delayed and 27 (8.6%) reduced (75% of doses) mainly for neutropenia and thrombocytopenia. IGEV-related toxic effects were mild with a relatively low incidence of grade 3 and 4 toxicity according to WHO Common Toxicity Criteria. Neutropenia was the most common hematologic toxicity, with grades 3-4 in 28% of courses. Platelet transfusion support was required in 15 cycles (4.4%), and red blood cells were transfused in 27 cycles (7.9%). Nausea and vomiting were mild and stomatitis occurred in 2% of patients. Peripheral neurotoxicity never exceeded grade II. Eleven grade II infections (3.0%) were documented, but all patients recovered rapidly.
Engraftment data
At present, engraftment data on 81 patients are available. Thirty-four patients received a single high-dose therapy procedure with thiotepa-melphalan, and 47 received tandem transplantation. One patient died from septic shock during the aplasia period following BCNU, etoposide, cytarabine, melphalan. Another patient died for unknown reasons the day after discharge from the bone marrow unit. After thiotepa-melphalan, the median number of reinfused CD34 þ cells was 11 (range 3-39) Â 10 6 /kg, whereas in patients treated with tandem transplant the median number of reinfused CD34 þ cells was 4.5 Â 10 6 /kg (range 3-8.9) and 5 Â 10 6 /kg (range 3-12) after MEL200 and BEAM, respectively. Following thiotepa-melphalan, neutrophil recovery and platelet recovery were achieved after a median time interval of 10 (range 8-28) and 8 days (range 6-38), respectively. As for tandem HDCT, following both HDCT courses, the median time period to ANC 40.5 Â 10 9 /l was 11 days (range 3-28), whereas a platelet count 420 Â 10 9 /l was reached after 7.5 and 8 days following MEL200 and BCNU, etoposide, cytarabine, melphalan, respectively. The mean number of transfused platelets, red cell units and duration of fever following thiotepa and melphalan administration, and after the first and second HDCT of a tandem transplant were similar. No correlation was found between the number of CFU-GM or CD34 þ cells reinfused, prior radiotherapy, the number of chemotherapy cycles and other factors, on the one hand, and the number of days to engraftment, on the other.
Costs
The mean cost of IGEV administered for four cycles was approximately 2800 Euros (700 Euros per course). This cost included the cost of the drugs, as well as their preparation and administration, and it is not much more than the common chemotherapy regimen used in relapsed/progressing HL (see Table 5 ). Furthermore therapy was administered on an outpatient basis and the very low hematological and non-hematological toxicity profile resulted in low toxicity-related costs.
Discussion
The current standard approach for relapsed/refractory HL consists of induction salvage therapy followed by HDCT plus PBSC support. 1, 4 However, the best approach in terms of response rate and PBSC mobilization is still under investigation. Several platinum (DHAP, ASHAP or ESHAP) and ifosfamide-based (ICE, MIME, VIP, IIVP) combinations have been explored with superimposable results in terms of response rate ranging from 8 to 69% (Table 5) . Recently, a high CR rate has been reported with a combination of ifosfamide, vinorelbine and gemcitabine, 20 supporting the use of this combination as pretransplant regimen in this patient subset.
The IGEV regimen was based on the results of previous trials including vinorelbine, gemcitabine and ifosfamide as single agents and ifosfamide plus vinorelbine. In various phase II studies, vinorelbine, as a single agent, showed response rates ranging from 35 to 90% even in patients already given vinca alkaloids and/or epipodophyllotoxins, 22 and ifosfamide given at high doses circumvented resistance to conventional doses of alkylating agents. 23 The efficacy of the combination of ifosfamide and vinorelbine as salvage and mobilizing stem cell regimen for poor prognosis lymphoma has been demonstrated. 7, 8, 24 Furthermore, several studies have suggested the efficacy of gemcitabine as single-agent therapy in patients with recurrent or refractory HL. 25, 26 A multicenter trial of 23 patients demonstrated an overall response rate of 39%, with a very low toxicity profile. 27 The mobilizing potential of the IGEV regimen has been investigated in this report, and the following findings have emerged.
The IGEV regimen followed by a fixed dose of lenograstim is an effective method for mobilization of CD34 þ cells. In the present series, a successful harvest was obtained in 99% of patients, with only one failed attempt that reached 2.3 Â 10 6 CD34 þ , which is considered sufficient to support an HDCT procedure.
The use of this regimen resulted in the successful collection of an adequate number of CD34 þ cells Abbreviations: ABVD ¼ adriamycin, bleomycin, vincristine, dacarbazine; IGEV ¼ ifosfamide, gemcitabine, vinorelbine and prednisone. Significant P-value is in bold. 1-3 and 2, range 1-3) per apheresis procedure for patients eligible for single high-dose treatment, and for candidates to tandem transplant, respectively. The required number of CD34 þ cells were harvested after a single leukapheresis in about two-thirds of the patients.
Furthermore, IGEV and a fixed dose of lenograstim produced good mobilization results even in patients 470kg.
These high levels of stem cell mobilization are comparable to the results obtained with DHAP regimen with over 95% successful stem cell mobilizations reported; 10, 19 however, these involved higher doses of G-CSF and patients who were able to receive only one transplant procedure. In the largest series reported in the literature, Smardova et al. 19 achieved a 97% rate of successful CD34 þ collection in 105 patients after DHAP, but by mobilizing patients with a high dose of G-CSF (10 mg/kg/day), after the first cycle of chemotherapy, and requiring a minimum CD34 þ harvest of 2 Â 10 6 /kg. 19 In our study, PBSC collection was performed after the first or second course in only 11 patients, in order to test the mobilizing potential of the regimen. It was subsequently performed after a third course in the other patients, whenever an objective response was observed.
With reference to a fixed dose of G-CSF, to our knowledge, only one study in the literature has so far been reported on the use of chemotherapy plus a fixed dose of G-CSF for mobilizing HL patients. Akhtar et al. 28 achieved a 97% mobilization rate by using ESHAP plus G-CSF 300 mg s.c. b.i.d in 131 HL and non-HL patients. In this study, less than half of the patients weighed X60 kg, and as a result most of them received over 10 mg/kg/day of G-CSF.
